Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Telithromycin · 5 trials · 6 indications
| Name | Type | Description |
|---|---|---|
| telithromycin (HMR3647) | DRUG | - |
| Telithromycin | DRUG | - |
Inclusion Criteria: * Outpatients of weight from 7.0 kg. * For respiratory tract infections:subjects diagnosed with mild or moderate respiratory tract infection (excluding pneumonia) based on a fever (≥ 38°C) or C-Reactive Protein positive, clinical symptoms/signs, and laboratory findings. * For de...
Telithromycin is an investigational small molecule antibiotic being studied for respiratory and related infections, including acute exacerbations of asthma, maxillary sinusitis, acute otitis media, and community-acquired pneumonia. It is developed by Sanofi and has completed Phase 3 clinical trials for these indications.
Telithromycin is a ketolide antibiotic that works by binding to the bacterial ribosome, inhibiting protein synthesis. It is designed to treat respiratory tract infections caused by susceptible bacteria, including those resistant to macrolides. The drug is being studied for its efficacy in conditions like sinusitis and pneumonia.
Telithromycin is developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi has conducted Phase 3 clinical trials to evaluate the drug's safety and efficacy in treating respiratory infections.
Telithromycin is in Phase 3 clinical development, with all four completed trials having reached this stage. It is not yet approved by regulatory authorities and remains investigational. The completed trials include studies in asthma, maxillary sinusitis, otitis media, and pneumonia.
Telithromycin has completed four Phase 3 trials: NCT00273520 (TELICAST) for acute asthma exacerbations, NCT00537563 comparing telithromycin to moxifloxacin in maxillary sinusitis, NCT00638534 for acute otitis media in children, and NCT00638859 for community-acquired pneumonia in children. All trials are completed.
Telithromycin is the generic name for the drug marketed under the brand name Ketek. It is developed by Sanofi and has been studied in Phase 3 trials for respiratory infections. The drug is not yet approved and remains in clinical development.